Frontlight ResearchEarly access
CompletedNo phase
Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)
Key facts
- Who runs it
- Ohio State University
- Where
- Columbus, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 56 people enrolled
- Started
- 1 Dec 2021
- Ended
- 15 Dec 2023
- Type of study
- Observational, 2 groups
- Treatments tested
- Nifedipine XL
- Record updated
- 22 December 2023
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Women age 18-45 with a viable single or twin intrauterine pregnancy between 22 0/7 and 33 6/7 weeks gestation based on the best obstetric estimate by ACOG criteria
- Undergoing expectant management for a diagnosis of preeclampsia with severe features and already initiated on 30mg Nifedipine XL. The patient may or may not have already received acute treatment for severe blood pressures
Who cannot take part
- Participation in another trial without prior approval
- Currently receiving a daily dose of Nifedipine XL of 60mg or greater
- Continuation of alternate long-acting anti-hypertensive medication on admission
- Known allergy or adverse reaction to Nifedipine or any medical condition where Nifedipine is contraindicated, such as galactose intolerance, severe GI stricture, and GI hypomotility disorder
- Physician/provider or patient refusal
- Triplet or higher order pregnancy
Where in United States
- The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal MedicineColumbus, United States
About the trial
What the trial wants to find out
The investigators propose a randomized controlled unblinded trial to evaluate rates of optimal blood pressure control between Nifedipine 60mg XL once daily vs. Nifedipine 30mg XL twice daily in patients admitted for expectant management with pre-eclampsia with severe features. Patients will be approached for consent when they are placed on 30mg of Nifedipine daily by their primary provider and will be enrolled in the study when the primary provider has made the decision to increase the patient's daily dose of Nifedipine XL from 30mg to 60mg.
The 2 groups in the trial
- Once daily Nifedipine XL 60mg
Participants will receive Nifedipine XL once daily 60 mg for 48 hours.
Treatment: Nifedipine XL
- Twice daily Nifedipine XL 30mg
Participants will receive Nifedipine XL twice daily 30 mg for 48 hours.
Treatment: Nifedipine XL
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Frequency and Dosing of Long Acting Anti-Hypertensive Agent in Women With Pre-eclampsia With Severe Features Undergoing Expectant Management: A Randomized Controlled Trial
- Record updated
- 22 December 2023